A recent alliance between Novartis and Siegfried laboratories seeks to strengthen the supply of high-quality drugs in Colombia.
Since August, this agreement grants exclusivity to the Latin American pharmaceutical company Siegfried to promote and commercialize three products that are part of the company’s cardiometabolic portfolio for patients with hypertension and diabetes problems. .
“With this alliance we achieve two major objectives: the first is to reach more patients with these two pathologies, and the second is that it allows us to concentrate our efforts on bringing innovative medicines to Colombia”, says Pedro Lückmann, commercial director and strategic alliances of Novartis Colombia.
–
For Siegfried, a company focused on the development, production and marketing of pharmaceutical, dermatological and nutritional products with more than 100 years of existence in Latin America, this alliance will represent an increase of up to 40% in their sales per year, an increase that will allow them to increase its presence in Colombia.
Paulo Etcheverry, Siegfried’s regional manager, comments that although they already have alliances with Novartis in Mexico, Brazil, Ecuador, and in some Central American and Caribbean countries, this is the first alliance they have made in Colombia.
Etcheverry stressed that these alliances are a reflection of the trust that these pharmaceutical houses have in Colombia and its health system.
– .
